Navigation Links
Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
Date:11/2/2007

in the placebo group than in the treated arms of this study. Safety is an important aspect of new HCV therapies, because the current standard of care is not always as well tolerated as desired."

The R7128 scientific presentation will be available for download in PDF format following the conference in the "R7128 Presentations & Publications" section of Pharmasset's website at http://www.pharmasset.com/pipeline/R7128-publications.asp.

R7128 Phase 1 Multiple Ascending Dose Study Overview

The Phase 1 clinical trial is a multiple center, observer-blinded, randomized and placebo-controlled study was conducted in 40 patients chronically-infected with HCV genotype 1 who previously failed interferon therapy. The primary objective was to assess the safety, tolerability and pharmacokinetics of R7128 after once-daily (QD) or twice-daily (BID) dosing for 14 days. The secondary objective was to assess antiviral activity by measuring the change in HCV RNA.

R7128 Safety Summary

R7128 was generally safe and well tolerated, and all patients completed the study. There were no serious adverse events, no adverse events requiring dose modification, no dose-related gastrointestinal adverse events and no clinically significant changes in hematologic or other laboratory parameters. The preliminary data on adverse events (AEs) reported shows the highest incidence of AEs was in the placebo group with 34 events in 7 of 8 patients receiving placebo. During treatment in patients receiving R7128, most of the AEs reported were of mild intensity. Eighteen AEs were reported in 7 of 8 subjects that received 750mg QD, 6 AEs in 3 of 8 subjects receiving 1500mg QD, 13 AEs in 4 of 8 subjects receiving 750mg BID and 14 AEs in 4 of 8 subjects receiving 1500mg BID. The most frequently reported AEs for patients receiving R7128 were headache (13), dry mouth (3), nausea (2), fatigue (2), tiredne
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
2. IDM Pharma Presents Preliminary Results of Melanoma Vaccine Clinical Trial
3. Living Liver Donor Who Saved Life of Mother-in-law Represents Cedars-Sinai in Rose Parade
4. Childrens Hospital Boston Presents at the Society for Adolescent Medicine Annual Meeting
5. Monogram Presents Results of First ETag Breast Cancer Studies
6. Novagali Pharma Presents Phase III Clinical Trial of Vekacia(R) for Vernal Keratoconjunctivitis
7. Novel Actemra monotherapy in treating patients with early aggressive rheumatoid arthritis
8. Combination Therapy More Effective Than Monotherapy for Treating Migraine
9. Rural Canadians travel far for specialists: study
10. A new study surpasses Gene Therapy Hurdle
11. Tomato Sauce reduces Cancer Risk- Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 31, 2014 Monica Williams-Murphy MD ... all too well the chaos that can occur for ... “The vast majority of Americans who come into the ... are completely unprepared for the moment and so are ... can serve as a catalyst for a family to ...
(Date:10/31/2014)... With all the preparations families carry ... they may overlook one critical area – the potential ... school performance and even behavior. Typical children’s vision screenings ... progressive vision problems, and to address this challenge, Dr. ... initiative: The Awesome Eyes Student Vision Program. , ...
(Date:10/31/2014)... 2014 (HealthDay News) -- Surgery for low back pain ... the United States you live, a new report says. ... back pain at some point in their lives, and ... care for a spine problem," co-author Brook Martin, of ... said in a college news release. In spinal ...
(Date:10/31/2014)... of treatment and cost, patients with early stage ... irradiation (APBI) with proton therapy versus whole breast ... University of Texas MD Anderson Proton Therapy Center. ... based on typical patient characteristics, researchers used Medicare ... different types of partial and whole breast irradiation ...
(Date:10/31/2014)... a lab device to give cancer researchers an unprecedented ... cells spread through the body, causing more than 90 ... how tumor cells travel, the device could uncover new ... from the university,s Whiting School of Engineering and its ... their new system recently in the journal Cancer ...
Breaking Medicine News(10 mins):Health News:This Thanksgiving or Christmas Family Gathering, Use The New App ListStuffFast to Start "The Conversation" With a Parent That Has No Plan For End-of-Life 2Health News:This Thanksgiving or Christmas Family Gathering, Use The New App ListStuffFast to Start "The Conversation" With a Parent That Has No Plan For End-of-Life 3Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Viewing cancer on the move: New device yields close-up look at metastasis 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 3
... dose to the breast and lungs before deciding which CT ... new study cautions. The study compared organ doses to ... found a change in protocol could decrease breast radiation dose ... breast skin and parenchyma were found with our standard thoracic ...
... or anxiety states are often associated with disturbances ... are compounds that are released from the synapses ... of neighboring neurons. Thus, as their name suggests, ... serotonin transporter (SERT) is responsible for reuptake of ...
... PROVIDENCE, R.I. Peter J. Snyder, Ph.D., vice president ... 10 Ig Nobel Prize awards during the annual ceremony ... and colleagues from the University of Melbourne and Yale Medical ... acute urge to void the bladder can have the same ...
... at least on the healthy part. "Early to bed and early ... youths keep slimmer and more physically active than their night-owl peers, ... A study in the Oct. 1 issue of the journal ... participants, ages 9 to 16, and compared their weights and uses ...
... New America Media (NAM) have selected 16 reporters for ... in its second year. They represent a wide range of mainstream ... Arizona to Korea Daily Atlanta. The fellows will convene during ... to 22 in Boston and tap into over 500 presentations ...
... -- Working rotating shifts is not as potentially unhealthy ... research that suggests modern shift patterns may not carry ... shift schedules. "Recent research has suggested shift work ... mechanism responsible for this observation is still unknown," the ...
Cached Medicine News:Health News:Combating mood disorders 2Health News:Lifespan researcher wins Ig Nobel Prize 2Health News:Early to bed and early to rise -- study suggests it's keeping kids leaner 2Health News:Journalism fellows promise in-depth portrayal of aging in a diverse America 2Health News:Journalism fellows promise in-depth portrayal of aging in a diverse America 3Health News:Journalism fellows promise in-depth portrayal of aging in a diverse America 4Health News:Modern Shift Work Patterns May Be Less Harmful to Health 2
(Date:10/31/2014)... 31, 2014 Mast Therapeutics, Inc. (NYSE MKT: ... for the quarter ended September 30, 2014. ... said:  "The third quarter was productive for Mast. Consistent with ... MST-188 for sickle cell disease is on track to ... have opened 50 study sites in the U.S. and ...
(Date:10/31/2014)... October 31, 2014 Oramed ... pharmaceutical company focused on the development of oral ... host a conference call to discuss the clinical ... ORMD-0801, the company,s proprietary oral insulin capsules, to ... 2014 at 10:00 a.m. Eastern time. ...
(Date:10/31/2014)... Investor-Edge has initiated coverage on the following ... Pharmaceuticals Inc. (NASDAQ: ISIS ), Halozyme Therapeutics ... (NASDAQ: ACAD ), and Synta Pharmaceuticals Corporation ... be accessed at: http://investor-edge.com/register . On ... 4,566.14, up 0.37%, the Dow Jones Industrial Average advanced ...
Breaking Medicine Technology:Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 4Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 5
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: